Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-09-21
Based on 598 first isolates · SURG · Skin / wound infection · 2024-09-22 → 2025-09-21
Surgery
Per-organism detail: SURG wound resistance view →
No single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 56 % (52 %–60 %)
Best two-drug combination: vancomycin + meropenem covers 99 % (98 %–100 %)
Take cultures before treatment; consider a combination and discuss with infectious diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (13 %), Escherichia coli (12 %), Proteus mirabilis (8 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
vancomycin VAN
trend · Staphylococcus aureus Gram-positive only
56 %
50 %
n = 58
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
44 %
40 %
n = 58
meropenem MEM
trend · Pseudomonas aeruginosa reserve
43 %
48 %
n = 58
piperacillin-tazobactam TZP
trend · Pseudomonas aeruginosa broad spectrum
41 %
45 %
n = 58
41 %
48 %
n = 58
ceftriaxone CRO
trend · Escherichia coli
27 %
34 %
n = 58
25 %
31 %
n = 58
22 %
19 %
n = 58
11 %
10 %
n = 58
mecillinam MEC
not for this site
0 %
0 %
n = 58
trimethoprim TMP
not for this site
0 %
0 %
n = 58
nitrofurantoin NIT
not for this site
0 %
0 %
n = 58

Most likely organisms for this profile

Staphylococcus aureus
46 %
Pseudomonas aeruginosa
13 %
Escherichia coli
12 %
Enterococcus faecalis
10 %
Proteus mirabilis
8 %
Citrobacter freundii
6 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.